These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
714 related articles for article (PubMed ID: 28321124)
1. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124 [TBL] [Abstract][Full Text] [Related]
2. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150 [TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph Willmann M; Sadovnik I; Eisenwort G; Entner M; Bernthaler T; Stefanzl G; Hadzijusufovic E; Berger D; Herrmann H; Hoermann G; Valent P; Rülicke T Exp Hematol; 2018 Jan; 57():50-59.e6. PubMed ID: 29031704 [TBL] [Abstract][Full Text] [Related]
5. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716 [TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Nguyen T; Dai Y; Attkisson E; Kramer L; Jordan N; Nguyen N; Kolluri N; Muschen M; Grant S Clin Cancer Res; 2011 May; 17(10):3219-32. PubMed ID: 21474579 [TBL] [Abstract][Full Text] [Related]
7. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors. Zhou Z; Liu T; Zhang J Biochem Biophys Res Commun; 2019 Dec; 520(3):560-565. PubMed ID: 31615652 [TBL] [Abstract][Full Text] [Related]
8. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894 [TBL] [Abstract][Full Text] [Related]
9. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis. Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079 [TBL] [Abstract][Full Text] [Related]
10. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Carter BZ; Mak DH; Shi Y; Schober WD; Wang RY; Konopleva M; Koller E; Dean NM; Andreeff M Cell Cycle; 2006 Oct; 5(19):2223-9. PubMed ID: 16969080 [TBL] [Abstract][Full Text] [Related]
11. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311 [TBL] [Abstract][Full Text] [Related]
12. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins. You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193 [TBL] [Abstract][Full Text] [Related]
13. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
14. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway. Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520 [TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. Jamieson CH; Ailles LE; Dylla SJ; Muijtjens M; Jones C; Zehnder JL; Gotlib J; Li K; Manz MG; Keating A; Sawyers CL; Weissman IL N Engl J Med; 2004 Aug; 351(7):657-67. PubMed ID: 15306667 [TBL] [Abstract][Full Text] [Related]
17. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597 [TBL] [Abstract][Full Text] [Related]
18. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Carter BZ; Mak PY; Mu H; Zhou H; Mak DH; Schober W; Leverson JD; Zhang B; Bhatia R; Huang X; Cortes J; Kantarjian H; Konopleva M; Andreeff M Sci Transl Med; 2016 Sep; 8(355):355ra117. PubMed ID: 27605552 [TBL] [Abstract][Full Text] [Related]
19. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Jin B; Wang C; Li J; Du X; Ding K; Pan J Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973 [TBL] [Abstract][Full Text] [Related]
20. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]